Nucala
Named-patient access overview. Nucala is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Nucala (mepolizumab) is an anti-interleukin-5 (anti-IL-5) monoclonal antibody developed by GlaxoSmithKline (GSK). The US Food and Drug Administration first approved Nucala in November 2015 for severe eosinophilic asthma in adults aged 12 years and older, with subsequent approvals expanding into eosinophilic granulomatosis with polyangiitis (EGPA, 2017), hypereosinophilic syndrome (HES, 2020), chronic rhinosinusitis with nasal polyps (CRSwNP, 2021), and asthma in paediatric patients aged 6 to 11 years.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Nucala
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Nucala is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Nucala in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Nucala
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.